Moderna, Inc. $MRNA Stock: ProShare Advisors LLC Boosts Position

ProShare Advisors LLC boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 6.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,898 shares of the company’s stock after buying an additional 4,277 shares during the period. ProShare Advisors LLC’s holdings in Moderna were worth $14,423,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Western Pacific Wealth Management LP purchased a new position in Moderna during the 3rd quarter valued at about $29,000. Allied Private Wealth LLC bought a new stake in shares of Moderna during the second quarter valued at about $30,000. Archer Investment Corp bought a new stake in shares of Moderna during the second quarter valued at about $36,000. Ramsey Quantitative Systems bought a new stake in shares of Moderna during the third quarter valued at about $40,000. Finally, Assetmark Inc. lifted its holdings in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after buying an additional 208 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In related news, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the business’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the sale, the president directly owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 197,251 shares of company stock valued at $33,875,904. Insiders own 10.80% of the company’s stock.

Moderna Trading Down 0.4%

MRNA stock opened at $220.83 on Tuesday. The company has a market capitalization of $88.16 billion, a PE ratio of -27.64 and a beta of 1.09. Moderna, Inc. has a one year low of $22.28 and a one year high of $254.48. The company’s 50 day moving average price is $184.00 and its two-hundred day moving average price is $87.42. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the prior year, the company earned ($2.13) EPS. The firm’s revenue was up 2.1% on a year-over-year basis. As a group, analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on MRNA shares. Citigroup restated a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. TD Cowen reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Bank of America upped their target price on shares of Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Friday, August 28th. Finally, Morgan Stanley increased their target price on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $107.10.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.